Hemolytic Disease of the Fetus and Newborn: Recent Advances in Immunohematology, Diagnosis and Clinical Management – A Comprehensive Review

Hemolytic illness, an immune-mediated disease that can be fatal, is brought on by maternal alloantibodies against fetal red blood cell antigens inherited from the father. Fetal anemia, hyperbilirubinemia, hydrops fetalis, and, in extreme circumstances, perinatal mortality these placental-crossing maternal immunoglobulin G antibodies. The incidence of RhD linked HDFN has decreased significantly, however alloimmunization against other blood group antigens such Kell, Rh c, Rh E, Duffy, Kidd, and ABO antigens still causes clinically significant disease. Thus, HDFN remains a significant concern in the fields of immunohematology, transfusion medicine, obstetrics, and neonatology. This review aims to present the current knowledge of the immunohematological mechanism of maternal alloimmunization and fetal hemolysis, especially focusing on clinically important blood group systems and antibody characteristics. Recent prenatal diagnostic developments, There have been notable advancements in early diagnosis and risk stratification of affected pregnancies because of advancements in technology like MCA-PSV Doppler ultrasound, molecular immunohematology, high throughput genotyping, and cell-free fetal DNA for non-invasive fetal blood type genotyping. Newer management techniques, including serial maternal antibody monitoring, intrauterine transfusion, optimized timing of delivery, neonatal phototherapy, exchange transfusion and evidence-based transfusion support, have dramatically improved the survival of fetuses and minimized disease-related complications. In addition, new technologies and innovations such as those based on artificial intelligence that can predict risk, digital immunohematology, automated compatibility testing, FcRn inhibitors, complement targeted therapies, and personalized immunotherapeutic strategies will help further define the diagnosis and management of HDFN. Nevertheless, the world faces many obstacles to achieving these advances, including the lack of access to molecular diagnostics, availability of appropriate blood products, and unequal distribution of health care services. Further multidisciplinary teamwork, technological innovations, and standardized clinical approaches will play a key role in furthering the goals of precision medicine and improving maternal and neonatal outcomes in the management of HDFN.